Champions Oncology Statistics Share Statistics Champions Oncology has 13.78M
shares outstanding. The number of shares has increased by 1.71%
in one year.
Shares Outstanding 13.78M Shares Change (YoY) 1.71% Shares Change (QoQ) 0% Owned by Institutions (%) 43.19% Shares Floating 5.2M Failed to Deliver (FTD) Shares 2,567 FTD / Avg. Volume 7.68%
Short Selling Information The latest short interest is 94.77K, so 0.69% of the outstanding
shares have been sold short.
Short Interest 94.77K Short % of Shares Out 0.69% Short % of Float 1.67% Short Ratio (days to cover) 3.19
Valuation Ratios The PE ratio is 20.78 and the forward
PE ratio is 31.5.
Champions Oncology's PEG ratio is
-0.13.
PE Ratio 20.78 Forward PE 31.5 PS Ratio 0 Forward PS 1.5 PB Ratio 25.89 P/FCF Ratio 13.96 PEG Ratio -0.13
Financial Ratio History Enterprise Valuation Champions Oncology has an Enterprise Value (EV) of 93.99M.
EV / Sales 0 EV / EBITDA 20.64 EV / EBIT 12.73 EV / FCF 13.43
Financial Position The company has a current ratio of 0.94,
with a Debt / Equity ratio of 1.62.
Current Ratio 0.94 Quick Ratio 0.94 Debt / Equity 1.62 Debt / EBITDA 1.34 Debt / FCF 0.87 Interest Coverage 0
Financial Efficiency Return on Equity is 124.63% and Return on Invested Capital is 46.44%.
Return on Equity 124.63% Return on Assets 14.53% Return on Invested Capital 46.44% Revenue Per Employee n/a Profits Per Employee $22.39K Employee Count 210 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -75K Effective Tax Rate -1.62%
Stock Price Statistics The stock price has increased by 60.94% in the
last 52 weeks. The beta is 0.51, so Champions Oncology's
price volatility has been higher than the market average.
Beta 0.51 52-Week Price Change 60.94% 50-Day Moving Average 7.2 200-Day Moving Average 7.8 Relative Strength Index (RSI) 48.32 Average Volume (20 Days) 33,409
Income Statement
Revenue n/a Gross Profit -28.39M Operating Income 4.55M Net Income 4.7M EBITDA 4.55M EBIT n/a Earnings Per Share (EPS) 0.34
Full Income Statement Balance Sheet The company has 9.79M in cash and 6.11M in
debt, giving a net cash position of 3.68M.
Cash & Cash Equivalents 9.79M Total Debt 6.11M Net Cash 3.68M Retained Earnings -79.89M Total Assets 32.34M Working Capital -1.48M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 7.39M
and capital expenditures -389K, giving a free cash flow of 7M.
Operating Cash Flow 7.39M Capital Expenditures -389K Free Cash Flow 7M FCF Per Share 0.51
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CSBR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 4.81% FCF Yield 7.16%
Dividend Details Analyst Forecast The average price target for CSBR is $12,
which is 75.4% higher than the current price. The consensus rating is "Strong Buy".
Price Target $12 Price Target Difference 75.4% Analyst Consensus Strong Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value $8.5 Lynch Upside 24.27% Graham Number 1.46 Graham Upside -78.65%
Stock Splits The last stock split was on Aug 12, 2015. It was a
backward
split with a ratio of 1:12.
Last Split Date Aug 12, 2015 Split Type backward Split Ratio 1:12
Scores Altman Z-Score 0.37 Piotroski F-Score 3
